DRG Market Assessment reports

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney…

Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidneys’ structure or function. To manage CKD and delay its progression to end-stage kidney…

Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…

The chronic kidney disease (CKD) therapy market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors to delay the progression of kidney damage. RAAS inhibitors are the standard…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. RAAS inhibitors are cornerstones of CKD treatment. SGLT-2…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…

Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive agents…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…

Clarivate Epidemiology’s coverage of CKD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total prevalence of CKD for each country, as well…

Clarivate Epidemiology’s coverage of chronic kidney disease (CKD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of CKD for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic kidney disease (CKD) patient populations covering 171…